Aligos Therapeutics Secures FDA Fast Track, Advances HBV Pipeline and Strengthens China Partnership

Main Programs Receive Key FDA Fast Track and Positive Trial Momentum

Aligos Therapeutics (NASDAQ: ALGS), a clinical-stage biotech, announced notable business progress for Q1 2026, headlined by its lead hepatitis B program, pevifoscorvir sodium, earning FDA Fast Track Designation. This milestone recognizes the critical unmet need in chronic HBV and the promise shown by Aligos’ therapy in recent clinical data. According to CEO Lawrence Blatt, the positive outcome of an interim analysis in the ongoing B-SUPREME Phase 2 study suggests strong momentum, with the trial continuing as planned after safety and futility criteria were favorably met.

B-SUPREME Study Expands with Encouraging Early Safety and Efficacy Signals

The interim analysis covered 34 HBeAg-negative participants and reviewed pooled safety data from all 174 enrollees, demonstrating that pevifoscorvir sodium was well tolerated with no concerning lab or ECG signals. The Drug Safety Monitoring Board recommended expanding enrollment in the HBeAg-negative arm from 74 to 100, increasing statistical power for the pivotal endpoint. No viral breakthrough has been observed in the study so far. Importantly, this marks the first randomized trial in newly diagnosed HBV patients using tenofovir as the active comparison and the most sensitive PCR assay (LLOQ <10 IU/mL) for HBV DNA assessment.

Strategic Partnership in Greater China Yields $25M Upfront, Up to $420M Milestones

Aligos has forged an exclusive partnership with Xiamen Amoytop Biotech to bring pevifoscorvir sodium to Greater China, aiming to accelerate regional approval. The deal brings $25 million in upfront cash, with the promise of up to $420 million in future milestones plus tiered, high single-digit royalties. This collaboration also supports development of ALG-170675, Aligos’ antisense oligonucleotide (ASO) candidate for HBV, where Amoytop funds current China-based R&D activities.

Pipeline Highlights: Phase 1 Matures, ASO Advances, MASH/Obesity Candidate Readies New Data

• Pevifoscorvir sodium: 96-week dosing now complete in Phase 1, with long-term data scheduled for presentation at EASL Congress 2026. Top-line Phase 2 (B-SUPREME) data for both trial cohorts (HBeAg+ and HBeAg-) are expected in 2027.
• ALG-170675 (ASO): IND-enabling studies underway, leveraging Amoytop’s support for China development; mechanism includes both mRNA destruction and immune activation.
• ALG-055009 (THR- for obesity, MASH): New nonclinical synergy data with incretin agonists will debut at upcoming scientific meetings. Funding options, including licensing, are being evaluated.

Financials Show Increased R&D Spend—Cash Runway Supported by Partnership

The company logged a net loss of $23 million in Q1 2026, primarily due to higher third-party trial costs as its lead program accelerates. Cash and investments stand at $54.91 million as of March 31, 2026. Management emphasizes that its cash runway extends into Q4 2026—including the imminent $25 million upfront from the Amoytop deal—supporting ongoing R&D and milestone-rich partnerships.

Upcoming Catalysts: Multiple Data Readouts in 2026–2027

Looking ahead, investors can anticipate:

• Further interim analysis from the B-SUPREME trial in the second half of 2026 and top-line data in 2027.
• Long-term phase 1 results for pevifoscorvir sodium at EASL 2026.
• Preclinical presentations for obesity and MASH candidate, ALG-055009, at major conferences.
• Steady progress and possible new Asia-based milestones via the Amoytop collaboration.

Takeaway: Progress in HBV Therapies Paired With Strong Partnerships Bolster Outlook

While Aligos posted a quarterly loss, the uptick in R&D and strong external validation via FDA Fast Track and Asian licensing position the company favorably as it approaches pivotal data milestones. With its robust cash runway and active business development, Aligos Therapeutics remains a company to watch for investors interested in innovative biotech solutions for liver and viral diseases.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI